0001209191-21-047402.txt : 20210720
0001209191-21-047402.hdr.sgml : 20210720
20210720170032
ACCESSION NUMBER: 0001209191-21-047402
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210719
FILED AS OF DATE: 20210720
DATE AS OF CHANGE: 20210720
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fust Matthew K
CENTRAL INDEX KEY: 0001397266
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38583
FILM NUMBER: 211101785
MAIL ADDRESS:
STREET 1: C/O ULTRAGENYX PHARMACEUTICAL INC.
STREET 2: 60 LEVERONI COURT
CITY: NOVATO
STATE: CA
ZIP: 94949
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Crinetics Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001658247
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 263744114
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-450-6464
MAIL ADDRESS:
STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-07-19
0
0001658247
Crinetics Pharmaceuticals, Inc.
CRNX
0001397266
Fust Matthew K
C/O CRINETICS PHARMACEUTICALS, INC.
10222 BARNES CANYON ROAD, BLDG 2
SAN DIEGO
CA
92121
1
0
0
0
Common Stock
2021-07-19
4
M
0
5000
1.91
A
17536
D
Common Stock
2021-07-19
4
S
0
5000
19.50
D
12536
D
Non-qualified stock option (Right to Buy)
1.91
2021-07-19
4
M
0
5000
0.00
D
2028-03-16
Common stock
5000
32092
D
The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.
Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter.
The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $19.50. The range of sales prices on the transaction date was $19.50 to $19.52 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
/s/ Marc Wilson, as attorney-in-fact
2021-07-20